McClellan takes to the airways
During a Jan. 15 appearance on National Public Radio's "Diane Rehm Show," Commissioner McClellan responded to questions about pressure from Congress to speed up approval times: "We do get pressure from Congress and other constituents...[but] I think we've got some win-win opportunities here." McClellan cited the additional resources and authorities afforded to the agency through the reauthorization of the Prescription Drug User Fee Act and noted that FDA will be expanding its staff for reviewing medical treatments and devices...
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.